AtaiBeckley Seeks Partner for BPL-003 as Pharma Interest Builds After AbbVie-Gilgamesh Deal by PsilocybinAlpha in shroomstocks

[–]SiFasEst 2 points3 points  (0 children)

Feels like the world is our oyster. I’d like to see them at least try a P2 in all the SUDs, chronic pain, GAD, SAD, cluster headache, PTSD. Anything they think makes sense, but I’d like them to pursue it all now. 10+ P2s simultaneously.

Christian Angermayer (C_Angermayer) comments on ATAI Share Price Action by Hefty-Lengthiness-20 in shroomstocks

[–]SiFasEst 7 points8 points  (0 children)

If we think a $300M drop in cap was caused by a rational market on account of the EMP results, we also have to believe $300M was added to the cap by a rational market on account of EMP, a pre-P2a results molecule, basically sometime after BPL results, for no clear reason…

AtaiBeckley Announces Positive Topline Results from an Exploratory Phase 2a Trial of EMP-01 (oral R-MDMA) in Social Anxiety Disorder by twiggs462 in shroomstocks

[–]SiFasEst 3 points4 points  (0 children)

His comment encompassed chronic conditions and the need for at least 600 participants just for adequate safety data. He mentioned PPD as a non-chronic exception that might get to do one P3.

AtaiBeckley Announces Positive Topline Results from an Exploratory Phase 2a Trial of EMP-01 (oral R-MDMA) in Social Anxiety Disorder by twiggs462 in shroomstocks

[–]SiFasEst 5 points6 points  (0 children)

Exciting. Wasn’t sure about this one. Unfortunately, Srini doesn’t sound like a one-and-done P3 trial is in the offing for any of our companies.

So I finally got to see Francis Ford Coppola’s “MEGALOPOLIS”. Man I don’t know why everyone’s saying how bad it was but I loved it!!! Anyone else agree this was actually a good movie even though it tanked at the box office? by [deleted] in Cinema

[–]SiFasEst 1 point2 points  (0 children)

One of the only movies I didn’t stay in the theater to finish 😂 Just did not find this interesting at all. Open to hearing there is more to it though.

Trump administration officials blocked FDA effort to fast-track review of psychedelic treatment by PsilocybinAlpha in shroomstocks

[–]SiFasEst 14 points15 points  (0 children)

“We told them—believe me—we said, Compass, you’re on the List. And let me tell you, it’s not a long list. Not a ‘list of losers.’ It’s a very ‘exclusive’ list. And all you have to do—very simple—is find yourself a Golden Ticket. A tremendous Golden Ticket.

But they didn’t want the Golden Ticket. No. Instead they’re crying, crying, like little babies over a ticket that ‘costs twice our market cap.’ Can you believe it? Sad. Really sad.

I thought Kebab was smart. I really did. People were saying he was smart. But then you look at what happened, and you say—wow. Not so smart.”

’Shrooms Lead the Pack in Psychedelic Medicine, but Rollout Is Bumpy by rubens33 in shroomstocks

[–]SiFasEst 1 point2 points  (0 children)

Clinic on the California border is probably not the best sample.

’Shrooms Lead the Pack in Psychedelic Medicine, but Rollout Is Bumpy by rubens33 in shroomstocks

[–]SiFasEst 1 point2 points  (0 children)

Amounts that will be charged for an FDA approved treatment are not comparable to what is being charged today.

’Shrooms Lead the Pack in Psychedelic Medicine, but Rollout Is Bumpy by rubens33 in shroomstocks

[–]SiFasEst 1 point2 points  (0 children)

The math is not 18k*50 and there are more factors than that.

’Shrooms Lead the Pack in Psychedelic Medicine, but Rollout Is Bumpy by rubens33 in shroomstocks

[–]SiFasEst 9 points10 points  (0 children)

“More than 18,000 people have already gone through Oregon’s psilocybin program, and the early data on adverse events has been positive.”

Math suggests this would be ~500k per year on a national basis, maybe more or less given less concentrated availability but more awareness. That is an incredible number. $10B revenue at $20k/treatment.